close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Eli Lilly (NY:LLY)

802.83 -16.55 (-2.02%)
Official Closing Price Updated: 7:00 PM EDT, Oct 17, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
99 100 Next >
$1000 Invested In This Stock 10 Years Ago Would Be Worth This Much Today
 
Via Benzinga
Trump's Pharma Tariffs Can Hit Novo Nordisk, Says Barclays Expert, But It's 'Difficult' To Predict As Drugmakers Have 'Complex Supply Chains'
Barclays has said that it's hard to predict which firm would be affected the most by pharma tariffs, except for Novo Nordisk. 
Via Benzinga
Topics Government World Trade
PolyPid’s Game-Changing 60-Day GLP-1 Platform Could Disrupt $100B Weight Loss Market
Via AB Newswire
Palatin’s Oral Obesity Drug Shows Remarkable Results: The Hidden Gem in the Weight Loss Race
Via AB Newswire
How Do Investors Really Feel About Eli Lilly?
 
Via Benzinga
This Is What Whales Are Betting On Eli Lilly
 
Via Benzinga
Goldman Spotlights These 3 Stocks in Its Bullish S&P 500 Outlook
Goldman Sachs raised its year-end S&P 500 forecast and identified three stocks that are poised to outperform in the second half of 2025: KSS, NTLA, and GOGO. 
Via MarketBeat
Topics Economy Stocks
10 Health Care Stocks Whale Activity In Today's Session
 
Via Benzinga
1 S&P 500 Stock for Long-Term Investors and 2 to Ignore
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all large-cap stocks are created equal - some... 
Via StockStory
Topics Stocks
Pfizer Faces $1 Billion IRA Reform Hit As Analysts Expect Flat 2025 Outlook
Pfizer faces a $1 billion sales hit in 2025 from IRA reforms, flat EPS and revenue forecasts, and long-term risks tied to patent expirations. 
Via Benzinga
Topics Intellectual Property
How To Trade This 150% Gainer Chasing A Cure For Type 1 Diabetes
An update on Sana Biotechnology. 
Via Benzinga
This Is 'One Of The Hottest Stocks In The Universe,' Jim Cramer Says
Rocket Lab notched its fastest launch turnaround ever, completing its 68th Electron mission and signaling a new era of rocket deployment. 
Via Benzinga
3 Dividend Growth Stocks to Buy and Hold
Via The Motley Fool
Topics Intellectual Property
Market Whales and Their Recent Bets on LLY Options
 
Via Benzinga
A Glimpse Into The Expert Outlook On Eli Lilly Through 7 Analysts
 
Via Benzinga
Trump Threatens 200% Pharma Tariffs, But Analyst Says This Stock Is Immune And Expected To 'Benefit' From Levies
Donald Trump's proposed 200% tariffs can squeeze the profit margins of pharma companies, but LLY is poised to "benefit" except for the rest. 
Via Benzinga
Topics Government World Trade
Eli Lilly And Company Stock: U.S. FDA Approves Safer Kisunla Dosing For Early Alzheimer’s
Eli Lilly stock has risen over 400% in 5 years despite a recent pullback. 
Via Talk Markets
Are Growth Stocks Back? 3 That Look Like Winners to Buy Now
Three companies are outpacing the market by leading secular trends in medicine, artificial intelligence, and consumer brands, creating durable growth stories. 
Via MarketBeat
Topics Artificial Intelligence
3 Profitable Stocks Facing Headwinds
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow. 
Via StockStory
3 Reasons I Bought Novo Nordisk Stock Instead of Eli Lilly
Via The Motley Fool
Zepbound Powers Eli Lilly's Upbeat Q2 Outlook
BofA slightly raised Q2 estimates for Eli Lilly ahead of earnings as Zepbound sales improve; long-term forecasts for key drugs remain steady. 
Via Benzinga
Elon Musk-Led SpaceX Starlink Gets Final Regulatory Approval For Launch In India: Report
Reuters reported on Wednesday, citing three sources, that Starlink has cleared the only remaining regulatory hurdle for the satellite provider to enter the market. 
Via Stocktwits
FDA Approves New Dosing Schedule For Eli Lilly's Kisunla In Alzheimer's Treatment
Lilly's Kisunla gets FDA approval for a new dosing schedule that significantly lowers ARIA-E risk while maintaining amyloid plaque reduction. 
Via Benzinga
Eli Lilly’s Alzheimer’s Drug Gets US FDA Label Update For More Gradual Dosing After Study Shows Reduced Side Effects
The U.S. FDA approved Kisunla, an amyloid-targeting therapy, in July 2024 after a study showed that it significantly slowed cognitive and functional decline in Alzheimer’s patients who were less... 
Via Stocktwits
Trump Threatens 200% Tariffs On Drug Imports, Says Big Pharma Will Get Some Time 'To Get Their Act Together'
Pharmaceutical investors are being cautious, with concerns over potential supply disruptions, cost pressures, and uncertainty regarding policy implementation. 
Via Stocktwits
Topics ETFs Economy Government
Don’t Miss Out: 3 Blue-Chips Set to Pop This Earnings Season
These 3 blue-chip stocks offer strong earnings power and growth opportunities as uncertainty lingers in the second half of 2025 
Via MarketBeat
Topics Economy World Trade
Trump Threatens To Slam Pharmaceuticals With Up To 200% Tariffs
President Donald Trump threatened Tuesday to levy up to 200% tariffs on drugs imported into the U.S. "very soon." 
Via Investor's Business Daily
Topics ETFs Economy Government
Does Higher Dose Of Wegovy Result In More Weight Loss? Novo Nordisk Seeks European Approval
Novo Nordisk seeks EMA approval for 7.2 mg Wegovy dose after trials show 21% weight loss in people with obesity and type 2 diabetes. 
Via Benzinga
WeightWatchers Sheds $1.15 Billion In Debt To Fuel Transformation
WeightWatchers completes reorganization, adds new leadership and unveils a women's health initiative targeting menopause care. 
Via Benzinga
LVM Capital Management Loads Up on NOC, Buys 6,237 Shares in Q2 2025
LVM Capital Management bought a $3.16 million stake in Northrop Grumman last quarter. 
Via The Motley Fool
Topics Regulatory Compliance
< Previous 1 2
...
16 17 18 19 20 21 22 23 24
...
99 100 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today